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Abstract
Introduction: Topiramate is a sulfamate-substituted monosaccharide mainly used to treat epilepsy
in children and adults and for prophylaxis of migraine. This article describes a case of topiramate
induced acute transient myopia. The underlying mechanism and management is discussed.
Case presentation: A 34-year-old female complained of sudden onset of blurred vision, 9 days
prior to this she had commenced topiramate therapy for migraine prophylaxis. Visual acuity was
reduced to 6/36 right eye and 2/60 left eye. Examination revealed ocular anatomical and myopic
refractive changes which resolved quickly following discontinuation of the drug.
Conclusion: Ophthalmologists need to be aware of the potential ocular side effects of topiramate.
Although relatively rare prompt recognition is key so appropriate management can be instituted.
Case presentation
A 34-year-old female complained of sudden onset of
blurred vision. She attended her optician who noted a
large myopic shift from –1.00/+0.50 ¥ 90 right eye,
-0.75/+0.25 ¥ 95 left eye to –3.50/+0.50 ¥ 90 right eye,
-3.50/+0.25 ¥ 95 left eye. Oral topiramate treatment had
been commenced for migraine prophylaxis 9 days prior to
the onset of her symptoms at a dose of 25 mg once daily
(OD), increased 7 days later to 50 mg OD. On examina-
tion Snellen visual acuity with her glasses on was 6/36
right eye, 2/60 left eye, with full new myopic correction
vision was 6/6 bilaterally. Both eyes were white and quiet
but anterior chambers were shallow and the iris and lens
were bowed forward. Intraocular pressures (IOP) were
18 mHg and Gonioscopy revealed 360
o Shaffer Grade 1.
No choroidal effusions were seen by indirect ophthalmo-
scopy but B-scan showed a small separation between the
choroidal and scleral layers bilaterally in keeping with
small effusions. Given the patient had discontinued the
topiramate therapy herself and as IOPs were normal
no treatment was instituted. At review 2 days later vision
with her glasses on had improved to 6/9 right eye, 6/36 left
eye. The anterior chambers were deep, IOP normal and the
iris and lens had returned to a normal position and
configuration. Two weeks later repeat Gonioscopy showed
360
o Shaffer Grade 4 angles, B-scan ultrasound showed
resolution of the choroidal effusions and refraction was
–0.75/+0.50 ¥ 100 right eye, -0.75/+0.50 ¥ 90 left eye,
with this correction vision was 6/5 bilaterally.
Discussion
As well as epilepsy and migraine topiramate has also been
used to treat depression, neuropathic pain, as a weight
reduction agent and for bipolar disorder. Case reports on
ocular side effects of this drug date back to 2001 [1-3]. In
September 2001 Ortho-McNeil Pharmaceuticals sent out a
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of secondary angle-closure glaucoma related to topiramate
use based on post-marketing experience in more than
825,000 patients. (Hulihan J: Important drug warning
[letter]. Available at: http://www.fda.gov/medwatch/
SAFETY/2001/topamax_deardoc.PDF).
The majority of reported adverse events have occurred in
female patients (up to 89%) [4]. Ocular side effects have
also been reported in children [5]. In the “certain” category
of the World Health Organisation classification system
adverse ocular side effects associated with topiramate
include abnormal vision, acute IOP elevation, acute
myopia (up to 8.75 dioptres), diplopia, nystagmus and
shallow anterior chamber with angle-closure. “Probable/
likely” include blepharospasm, myokymia, oculogyric
crisis, suprachoroidal effusions and “possible” are con-
genital ocular abnormalities, periorbital oedema and
scleritis [6]. High frequency ultrasound biomicroscopy,
anterior segment ocular coherence tomography and B-scan
ultrasound have helped establish and document the
underlying mechanism of the myopia and angle-closure
glaucoma [7-9] – uveal effusions and ciliary body oedema
result in antero-lateral rotation of the ciliary body, anterior
displacement of the lens-iris diaphragm which contributes
to the myopic shift, anterior chamber shallowing and
secondary appositional angle closure. The effusion and
oedema also lead to relaxation of the lens zonules
resulting in thickening of the lens further narrowing the
angle. Though the exact mechanism is unclear the fluid
movement leading to effusions is thought to be related
to drug induced changes in membrane potential [8]. In
reported cases of angle-closure glaucoma topiramate doses
varied from 50 mg or less to 100 mg or more, 5 reported
cases were precipitated within hours after doubling the
dose, 85% of cases occurred in the first 2 weeks of
treatment with the drug [10].
Fraunfelder et al [10] advise the following management
strategy for topiramate-associated angle-closure glaucoma:
Stoppage of the drug in the first instance, the prescribing
doctor should be consulted.
Medical therapy such as oral medications and aqueous
suppressants should be given.
Laser iridotomy or peripheral iridectomy are not helpful as
topiramate angle closure is not pupil block related.
Topical miotics may be contraindicated as they could
precipitate a relative pupil block.
Topical cycloplegic agents may be given as they possibly
lower IOP by retracting ciliary processes.
Care should be taken with acetazolamide as it is also a
sulfa-based drug and has been reported to cause angle-
closure glaucoma in a similar manner to topiramate [11].
In this case the topiramate induced anatomical changes
stopped short of inducing angle-closure glaucoma. The
rapid onset of visual loss secondary to the myopia is
understandably distressing to the patient and it is helpful
to be able to provide some guidance on prognosis – as the
mean plasma elimination half life of the drug is about 21
hours [12], rapid visual recovery usually occurs although
in some cases it can take several weeks [10]. If unrecog-
nised as a drug-related event serious outcomes could occur
(7 cases of permanent visual loss following angle-closure
glaucoma have been reported) [10]. Ocular examination
before starting topiramate cannot identify eyes at risk [8].
Patients commencing topiramate should therefore be
advised to immediately report any symptoms of eye pain
or blurred vision especially in the first few weeks of
treatment.
Conclusion
Ophthalmologists need to be aware of the potential ocular
side effects of topiramate. Although relatively rare prompt
recognition is key so appropriate management can be
instituted and visual outcomes maximised.
Abbreviation
IOP, Intraocular pressures.
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